Akaza Hideyuki, Kawahara Norie, Roh Jae Kyung, Inoue Hajime, Park Eun-Cheol, Lee Kwang-Sig, Kim Sukyeong, Hayre Jasdeep, Naidoo Bhash, Wilkinson Thomas, Fukuda Takashi, Jang Woo Ick, Nogimori Masafumi
Department of Strategic Investigation on Comprehensive Cancer Network, Research Center for Advanced Science and Technology, University of Tokyo, Japan E-mail :
Asian Pac J Cancer Prev. 2014;15(1):3-10. doi: 10.7314/apjcp.2014.15.1.3.
The Japan National Committee for the Union for International Cancer Control (UICC) and UICC-Asia Regional Office (ARO) organized an international session as part of the official program of the 72nd Annual Meeting of the Japanese Cancer Association to discuss the topic "What is cost-effectiveness in cancer treatment? " Healthcare economics are an international concern and a key issue for the UICC. The presenters and participants discussed the question of how limited medical resources can be best used to support life, which is a question that applies to both developing and industrialized countries, given that cancer treatment is putting medical systems under increasing strain. The emergence of advanced yet hugely expensive drugs has prompted discussion on methodologies for Health Technology Assessment (HTA) that seek to quantify cost and effect. The session benefited from the participation of various stakeholders, including representatives of industry, government and academia and three speakers from the Republic of Korea, an Asian country where discussion on HTA methodologies is already advanced. In addition, the session was joined by a representative of National Institute for Health and Care Excellence (NICE) of the United Kingdom, which has pioneered the concept of cost-effectiveness in a medical context. The aim of the session was to advance and deepen understanding of the issue of cost-effectiveness as viewed from medical care systems in different regions.
日本国际癌症控制联盟（UICC）全国委员会及UICC亚洲区域办公室（ARO）组织了一场国际会议，作为日本癌症协会第72届年会官方议程的一部分，以讨论“癌症治疗中的成本效益是什么？”这一主题。卫生保健经济学是一个国际关注的问题，也是UICC的一个关键问题。鉴于癌症治疗给医疗系统带来的压力日益增大，这一问题在发展中国家和工业化国家都存在，因此，演讲者和与会者讨论了如何最好地利用有限的医疗资源来维持生命。先进但极其昂贵的药物的出现引发了对卫生技术评估（HTA）方法的讨论，这些方法旨在量化成本和效果。本次会议受益于包括行业、政府和学术界代表在内的各利益相关方的参与，以及来自韩国的三位演讲者，韩国是一个在HTA方法讨论方面已经很先进的亚洲国家。此外，英国国家卫生与临床优化研究所（NICE）的一位代表也参加了本次会议，该机构在医疗背景下率先提出了成本效益的概念。本次会议的目的是从不同地区的医疗系统角度推进和加深对成本效益问题的理解。
